Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens

Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dos...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2005-02, Vol.40 (3), p.374-380
Main Authors: Raad, Issam, Darouiche, Rabih, Vazquez, Jose, Lentnek, Arnold, Hachem, Ray, Hanna, Hend, Goldstein, Beth, Henkel, Tim, Seltzer, Elyse
Format: Article
Language:English
Subjects:
Administered dose
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacteremia
Bacterial diseases
Biological and medical sciences
Blood
Catheters
Catheters, Indwelling - adverse effects
Clinical outcomes
Dosage
Drug Administration Schedule
Drug therapy
Female
General aspects
Glycopeptides
Human bacterial diseases
Human infectious diseases. Experimental studies and models
Humans
Infections
Infectious diseases
Major Articles
Male
Medical sciences
Middle Aged
Pathogens
Pharmacology. Drug treatments
Staphylococcal infections, streptococcal infections, pneumococcal infections
Staphylococcus aureus
Teicoplanin - adverse effects
Teicoplanin - analogs & derivatives
Teicoplanin - therapeutic use
Vancomycin - adverse effects
Vancomycin - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Catheter-related bloodstream infections (CR-BSIs) are associated with substantial mortality, prolongation of hospital stay, and increased cost of care. Dalbavancin, a new glycopeptide antibiotic with unique pharmacokinetic properties that have allowed clinical development of a weekly dosing regimen, possesses excellent activity against clinically important gram-positive bacteria, suggesting utility in the treatment of patients with CR-BSIs. Methods. A phase 2, open-label, randomized, controlled, multicenter study of 75 adult patients with CR-BSIs compared treatment with intravenous dalbavancin, administered as a single 1000-mg dose followed by a 500-mg dose 1 week later, with intravenous vancomycin, administered twice daily for 14 days. Gram-positive bacteria isolated in this study included coagulase-negative staphylococci (CoNS) and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). Results. Infected patients who received weekly dalbavancin (n = 33) had an overall success rate (87.0%; 95% confidence interval [CI], 73.2%–100.0%) that was significantly higher than that of those who received vancomycin (n = 34) (50.0%; 95% CI, 31.5%–68.5%). Adverse events and laboratory abnormalities were generally mild and were comparable for the 2 drugs. Conclusions. Dalbavancin thus appears to be an effective and well-tolerated treatment option for adult patients with CR-BSIs caused by CoNS and S. aureus, including MRSA.
ISSN:1058-4838
1537-6591
DOI:10.1086/427283